416 related articles for article (PubMed ID: 32973527)
1. Harnessing Memory NK Cell to Protect Against COVID-19.
Soleimanian S; Yaghobi R
Front Pharmacol; 2020; 11():1309. PubMed ID: 32973527
[TBL] [Abstract][Full Text] [Related]
2. Natural Killer Cells in SARS-CoV-2 Infection: Pathophysiology and Therapeutic Implications.
Di Vito C; Calcaterra F; Coianiz N; Terzoli S; Voza A; Mikulak J; Della Bella S; Mavilio D
Front Immunol; 2022; 13():888248. PubMed ID: 35844604
[TBL] [Abstract][Full Text] [Related]
3. Human Cytomegalovirus Antigen Presentation by HLA-DR+ NKG2C+ Adaptive NK Cells Specifically Activates Polyfunctional Effector Memory CD4+ T Lymphocytes.
Costa-García M; Ataya M; Moraru M; Vilches C; López-Botet M; Muntasell A
Front Immunol; 2019; 10():687. PubMed ID: 31001281
[TBL] [Abstract][Full Text] [Related]
4. Natural killer cells play an important role in virus infection control: Antiviral mechanism, subset expansion and clinical application.
Zuo W; Zhao X
Clin Immunol; 2021 Jun; 227():108727. PubMed ID: 33887436
[TBL] [Abstract][Full Text] [Related]
5. Late Development of FcεRγ
Muccio L; Falco M; Bertaina A; Locatelli F; Frassoni F; Sivori S; Moretta L; Moretta A; Della Chiesa M
Front Immunol; 2018; 9():1050. PubMed ID: 29868012
[TBL] [Abstract][Full Text] [Related]
6. Exhausted NK cells and cytokine storms in COVID-19: Whether NK cell therapy could be a therapeutic choice.
Ghasemzadeh M; Ghasemzadeh A; Hosseini E
Hum Immunol; 2022 Jan; 83(1):86-98. PubMed ID: 34583856
[TBL] [Abstract][Full Text] [Related]
7. Leukocyte Immunoglobulin-Like Receptor 1-Expressing Human Natural Killer Cell Subsets Differentially Recognize Isolates of Human Cytomegalovirus through the Viral Major Histocompatibility Complex Class I Homolog UL18.
Chen KC; Stanton RJ; Banat JJ; Wills MR
J Virol; 2016 Jan; 90(6):3123-37. PubMed ID: 26739048
[TBL] [Abstract][Full Text] [Related]
8. IL-12-producing monocytes and HLA-E control HCMV-driven NKG2C+ NK cell expansion.
Rölle A; Pollmann J; Ewen EM; Le VT; Halenius A; Hengel H; Cerwenka A
J Clin Invest; 2014 Dec; 124(12):5305-16. PubMed ID: 25384219
[TBL] [Abstract][Full Text] [Related]
9. Activating KIRs and NKG2C in Viral Infections: Toward NK Cell Memory?
Della Chiesa M; Sivori S; Carlomagno S; Moretta L; Moretta A
Front Immunol; 2015; 6():573. PubMed ID: 26617607
[TBL] [Abstract][Full Text] [Related]
10. NK cells and ILCs in tumor immunotherapy.
Sivori S; Pende D; Quatrini L; Pietra G; Della Chiesa M; Vacca P; Tumino N; Moretta F; Mingari MC; Locatelli F; Moretta L
Mol Aspects Med; 2021 Aug; 80():100870. PubMed ID: 32800530
[TBL] [Abstract][Full Text] [Related]
11. Siglec-9 Restrains Antibody-Dependent Natural Killer Cell Cytotoxicity against SARS-CoV-2.
Saini P; Adeniji OS; Bordoloi D; Kinslow J; Martinson J; Parent DM; Hong KY; Koshy J; Kulkarni AJ; Zilberstein NF; Balk RA; Moy JN; Giron LB; Tracy RP; Keshavarzian A; Muthumani K; Landay A; Weiner DB; Abdel-Mohsen M
mBio; 2023 Feb; 14(1):e0339322. PubMed ID: 36728420
[TBL] [Abstract][Full Text] [Related]
12. NKG2C(+)CD57(+) Natural Killer Cell Expansion Parallels Cytomegalovirus-Specific CD8(+) T Cell Evolution towards Senescence.
Heath J; Newhook N; Comeau E; Gallant M; Fudge N; Grant M
J Immunol Res; 2016; 2016():7470124. PubMed ID: 27314055
[TBL] [Abstract][Full Text] [Related]
13. Natural killer cells can inhibit the transmission of human cytomegalovirus in cell culture by using mechanisms from innate and adaptive immune responses.
Wu Z; Sinzger C; Reichel JJ; Just M; Mertens T
J Virol; 2015 Mar; 89(5):2906-17. PubMed ID: 25540381
[TBL] [Abstract][Full Text] [Related]
14. About Training and Memory: NK-Cell Adaptation to Viral Infections.
Hammer Q; Romagnani C
Adv Immunol; 2017; 133():171-207. PubMed ID: 28215279
[TBL] [Abstract][Full Text] [Related]
15. Memory and CAR-NK cell-based novel approaches for HIV vaccination and eradication.
Mazarzaei A; Vafaei M; Ghasemian A; Mirforughi SA; Rajabi Vardanjani H; Alwan NAS
J Cell Physiol; 2019 Sep; 234(9):14812-14817. PubMed ID: 30779120
[TBL] [Abstract][Full Text] [Related]
16. Flattening the COVID-19 Curve With Natural Killer Cell Based Immunotherapies.
Market M; Angka L; Martel AB; Bastin D; Olanubi O; Tennakoon G; Boucher DM; Ng J; Ardolino M; Auer RC
Front Immunol; 2020; 11():1512. PubMed ID: 32655581
[TBL] [Abstract][Full Text] [Related]
17. Glycoprotein Targeted CAR-NK Cells for the Treatment of SARS-CoV-2 Infection.
Christodoulou I; Rahnama R; Ravich JW; Seo J; Zolov SN; Marple AN; Markovitz DM; Bonifant CL
Front Immunol; 2021; 12():763460. PubMed ID: 35003077
[TBL] [Abstract][Full Text] [Related]
18. Adaptive natural killer cell response to cytomegalovirus and disability progression in multiple sclerosis.
Martínez-Rodríguez JE; Cobo-Calvo A; Villar LM; Munteis E; Blanco Y; Rasal R; Vera A; Muntasell A; Alvarez-Lafuente R; Saiz A; Alvarez-Cermeño JC; Martínez-Yélamos S; Roquer J; López-Botet M
Mult Scler; 2016 May; 22(6):741-52. PubMed ID: 26362897
[TBL] [Abstract][Full Text] [Related]
19. Extent of Cytomegalovirus Replication in the Human Host Depends on Variations of the HLA-E/UL40 Axis.
Vietzen H; Rückert T; Hartenberger S; Honsig C; Jaksch P; Geleff S; Hammer Q; Romagnani C; Segura-Wang M; Puchhammer-Stöckl E
mBio; 2021 Mar; 12(2):. PubMed ID: 33727352
[TBL] [Abstract][Full Text] [Related]
20. Natural killer cell biology: an update and future directions.
Campbell KS; Hasegawa J
J Allergy Clin Immunol; 2013 Sep; 132(3):536-544. PubMed ID: 23906377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
